<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04277884</url>
  </required_header>
  <id_info>
    <org_study_id>QGC001-3QG1</org_study_id>
    <nct_id>NCT04277884</nct_id>
  </id_info>
  <brief_title>Firibastat in Treatment-resistant Hypertension</brief_title>
  <acronym>FRESH</acronym>
  <official_title>A Phase 3, Double-blind, Placebo-controlled, Efficacy and Safety Study of Firibastat (QGC001) Administered Orally, Twice Daily, Over 12 Weeks in Difficult-to-treat/Resistant Hypertensive Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Quantum Genomics SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Quantum Genomics SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, placebo-controlled, multicenter, efficacy and safety study of
      firibastat (QGC001) administered po bid over 12 weeks in male and female subjects ≥18 years
      of age at Screening, with uncontrolled primary HTN. Subjects will be randomized 1:1 to
      investigational product (IP) and will receive either firibastat (QGC001) or matching placebo
      on top of their current chronic antihypertensive treatments.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to assess the effects of administration of firibastat
      (QGC001) 500 mg oral (po) twice daily (bis in die [bid]) on blood pressure (BP) over 12 weeks
      in subjects with uncontrolled primary HTN.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systolic Blood Pressure at office (mmHg)</measure>
    <time_frame>From Day 1 to Day 84</time_frame>
    <description>Automatic Office Blood Pressure measurement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure at office (mmHg)</measure>
    <time_frame>From Day 1 to Day 84</time_frame>
    <description>Automatic Office Blood Pressure measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean 24-hour ambulatory Systolic Blood Pressure (mmHg)</measure>
    <time_frame>From Day 1 to Day 84</time_frame>
    <description>Ambulatory Blood Pressure Monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean 24-hour ambulatory Diastolic Blood Pressure (mmHg)</measure>
    <time_frame>From Day 1 to Day 84</time_frame>
    <description>Ambulatory Blood Pressure Monitoring</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">502</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Firibastat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Firibastat</intervention_name>
    <description>Oral administration 2×250 mg capsules bid</description>
    <arm_group_label>Firibastat</arm_group_label>
    <other_name>QGC001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral administration 2 capsules bid</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women ≥18 years of age at Screening

          -  Diagnosis of primary HTN for at least 6 months prior to Screening

        Exclusion Criteria:

          -  Known or suspected secondary HTN (eg, hyperaldosteronism, renovascular HTN,
             pheochromocytoma, Cushing's disease).

          -  Automated office SBP &gt;170 mmHg or DBP &gt;110 mmHg at the Screening or Inclusion Visit
             (Visit 2, Day 1) and confirmed by a second measurement within 30 minutes to 1 hour.

          -  Known hypertensive retinopathy (Keith-Wagener Grade 3 or Grade 4) and/or hypertensive
             encephalopathy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Bakris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AHA Comprehensive Hypertension Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bruno Besse, MD</last_name>
    <phone>+33 1 85 34 77 73</phone>
    <email>bruno.besse@quantum-genomics.com</email>
  </overall_contact>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 17, 2020</study_first_submitted>
  <study_first_submitted_qc>February 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2020</study_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

